Quantification of cabazitaxel in human plasma by liquid chromatography/triple-quadrupole mass spectrometry: A practical solution for non-specific binding

Journal of Pharmaceutical and Biomedical Analysis

Volumn 59, Issue 1, 2012, Pages 117-122

  de Bruijn, Peter ^a   de Graan, Anne Joy M ^a   Nieuweboer, Annemieke ^a   Mathijssen, Ron H J ^a   Lam, Mei Ho ^a   de Wit, Ronald ^a   Wiemer, Erik A C ^a   Loos, Walter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cabazitaxel; Human plasma; LC MS MS; Non specific binding; Validated

Indexed keywords

ACETONITRILE; AMMONIUM HYDROXIDE; CABAZITAXEL; DEUTERIUM; LITHIUM;

ARTICLE; CALIBRATION; DILUTION; DRUG BINDING; DRUG DETERMINATION; ELUTION; FLOW RATE; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PLASMA; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; STANDARD; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; HUMANS; INFUSIONS, INTRAVENOUS; LIMIT OF DETECTION; MOLECULAR STRUCTURE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TAXOIDS;

EID: 82255179007     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.10.010     Document Type: Article

References (13)

1. Metzger-Filho O., Moulin C., de Azambuja E., Ahmad A. Larotaxel: broadening the road with new taxanes. Expert Opin. Investig. Drugs 2009, 18:1183-1189.
2. Michielsen D.P., Braeckman J.G., Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin. Pharmacother. 2011, 12:977-982.
3. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011, 7:497-506.
4. Assessment Report for Jevtana (Cabazitaxel), Procedure No.: EMEA/H/C/002018 2011, European Medicines Agency, London.
5. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., Roessner M., Gupta S., Sartor A.O. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
6. Pivot X., Koralewski P., Hidalgo J.L., Chan A., Goncalves A., Schwartsmann G., Assadourian S., Lotz J.P. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 2008, 19:1547-1552.
7. Villanueva C., Awada A., Campone M., Machiels J.P., Besse T., Magherini E., Dubin F., Semiond D., Pivot X. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study. Eur. J. Cancer 2011, 47:1037-1045.
8. Mita A.C., Denis L.J., Rowinsky E.K., Debono J.S., Goetz A.D., Ochoa L., Forouzesh B., Beeram M., Patnaik A., Molpus K., Semiond D., Besenval M., Tolcher A.W. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15:723-730.
9. Gelmon K.A., Latreille J., Tolcher A., Genier L., Fisher B., Forand D., D'Aloisio S., Vernillet L., Daigneault L., Lebecq A., Besenval M., Eisenhauer E. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 2000, 18:4098-4108.
10. de Bruijn P., Moghaddam-Helmantel I.M., de Jonge M.J., Meyer T., Lam M.H., Verweij J., Wiemer E.A., Loos W.J. Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50:977-982.
11. Rosing H., Man W.Y., Doyle E., Bult A., Beijnen J.H. Bioanalytical liquid chromatographic method validation. A review of current practices and procedures. J. Liq. Chromatogr. RT 2000, 23:329-354.
12. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.
13. Loos W.J., Zamboni W.C., Engels F.K., de Bruijn P., Lam M.H., de Wit R., Verweij J., Wiemer E.A. Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel. J. Pharm. Biomed. Anal. 2007, 45:288-294.